<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04907526</url>
  </required_header>
  <id_info>
    <org_study_id>21-000088</org_study_id>
    <nct_id>NCT04907526</nct_id>
  </id_info>
  <brief_title>Intramyocardial Injection of Autologous UCB-MNC During Fontan Surgery for SRV Dependent CHD</brief_title>
  <official_title>Phase I Study of Intramyocardial Injection of Autologous Umbilical Cord Blood-Derived Mononuclear Cells During Fontan Surgical Palliation of Single Right Ventricle-Dependent Congenital Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Timothy J Nelson, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospitals and Clinics of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Colorado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ochsner Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's of Alabama</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ReGen Theranostics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers want to better understand what happens to the heart when the autologous (from&#xD;
      one's own body) stem cells are injected directly into muscle of the right side of the heart&#xD;
      during the Fontan (Stage III) surgery. They want to see if there are changes in the&#xD;
      electrical activity, the structure, and the function of the heart following this stem&#xD;
      cell-based therapy. Researchers will compare the results from people who receive the stem&#xD;
      cells to the results from people who do not receive the stem cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase I study is a multicenter, prospective, open-label, non-randomized study designed&#xD;
      to evaluate the safety, of autologous UCB-MNC delivered into the right ventricular myocardium&#xD;
      of subjects with severe CHD defined by single right ventricular dependent circulatory systems&#xD;
      at the time of a planned Fontan surgical palliation. This will be achieved by comparing the&#xD;
      data collected in the treatment arm to the equivalent data collected in the control arm. The&#xD;
      purpose of this non-randomized open-label Phase I clinical study is to prospectively evaluate&#xD;
      the safety, as measured by the short-term and long-term safety endpoints and change in&#xD;
      baseline comparatives, for the autologous UCB-MNC intramyocardial injections into the single,&#xD;
      morphologically right ventricle of subjects with severe CHD requiring Fontan surgical&#xD;
      palliation. The treatment group will be compared to an untreated control group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short-term safety</measure>
    <time_frame>Within 3 months post Fontan surgery</time_frame>
    <description>Measure of new or worsening adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long term safety</measure>
    <time_frame>Within 2 years post Fontan surgery</time_frame>
    <description>Measure of new or worsening adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right ventricular function</measure>
    <time_frame>Baseline, hospital discharge (up to 30 days post Fontan surgery), 3 months post Fontan surgery</time_frame>
    <description>Change from baseline Transthoracic Echocardiogram right ventricular function as measured by biplane Fractional Area Change (FAC) at discharge and 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High sensitivity Troponin T</measure>
    <time_frame>3 hours post enrollment, 6 hours post enrollment, hospital discharge (up to 30 days post Fontan surgery)</time_frame>
    <description>Change from baseline in High sensitivity Troponin T at 3 hours and 6 hours after enrollment and at hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-pro-BNP</measure>
    <time_frame>Baseline, hospital discharge (up to 30 days post Fontan surgery), 3 months post Fontan surgery</time_frame>
    <description>Change from baseline in NT-pro-BNP levels compared to baseline, at hospital discharge and at 3 months post-Fontan surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Panel Reactive Antibody</measure>
    <time_frame>Baseline, hospital discharge (up to 30 days post Fontan surgery), 3 months post Fontan surgery</time_frame>
    <description>Change from baseline in PRA levels at discharge and 3 months post-Fontan surgery compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Baseline, 3 months post-Fontan surgery, 12 months post-Fontan surgery</time_frame>
    <description>Change from baseline in weight at 3 and 12 months post-Fontan surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative days hospitalization</measure>
    <time_frame>3 months post discharge, 12 months post discharge</time_frame>
    <description>Cumulative days of hospitalization per patient at 3 and 12 months post-Fontan surgery discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Parent Proxy Scale v1.0-Global Health 7</measure>
    <time_frame>Baseline, hospital discharge (up to 30 days post Fontan surgery), 3 months, 12 months, 18 months, 24 months</time_frame>
    <description>Change from baseline in PROMIS Parent Proxy Scale v1.0-Global Health 7 at discharge, 3, 12, 18, and 24 months post-Fontan surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Congenital Heart Disease, SRV Dependent</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous (self) mononuclear cells derived from umbilical cord blood and that meet all release criteria are injected into the surface of the right heart muscle to achieve the target dose of 3 million cells per kilogram of body weight. This is a one time treatment at the time of Stage III Fontan surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control cohort not receiving the cell product, which will be enrolled and followed using the same inclusion/exclusion criteria and follow-up requirements as the treatment arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous mononuclear cells</intervention_name>
    <description>Autologous mononuclear cells delivered into right ventricle at time of Stage III Fontan surgery.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of a congenital hear defect with functionally single right ventricle (such&#xD;
             as HLHS, HLHS variants, unbalanced AV septal defect with R dominance, DORV with&#xD;
             Hypoplastic LV) undergoing Fontan surgical palliation&#xD;
&#xD;
          -  At least 2 and less than or equal to 5 years of age at time of Fontan surgical&#xD;
             palliation&#xD;
&#xD;
          -  For subjects enrolling in the treatment arm, previous participation in clinical trial&#xD;
             Umbilical Cord Blood Collection and Processing for Hypoplastic Left Heart Syndrome&#xD;
             patients (NCT01856049) with autologous UCB-MNC product collected and available for&#xD;
             distribution is required.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of DMSO reaction (treatment arm only subjects).&#xD;
&#xD;
          -  Parent(s) or legal guardian unwilling to have their child participate or unwilling to&#xD;
             follow the study procedures.&#xD;
&#xD;
          -  Severe chronic diseases at the discretion of the treating physician.&#xD;
&#xD;
          -  Extensive extra-cardiac syndromic features.&#xD;
&#xD;
          -  History of cancer.&#xD;
&#xD;
          -  Any of the following complications of his/her congenital heart disease:&#xD;
&#xD;
               -  any condition requiring urgent, or unplanned intervention procedure within 15&#xD;
                  days prior to Fontan surgical palliation, unless complete and full cardiac&#xD;
                  recovery is documented by site investigator.&#xD;
&#xD;
               -  severe pulmonary hypertension (reported in the medical record as &gt;70% systemic&#xD;
                  pressure)&#xD;
&#xD;
               -  Other clinical concerns as documented by a site investigator that would predict&#xD;
                  (more likely to happen than not to happen) a risk of severe complications or very&#xD;
                  poor outcome, not directly related tot he stem cell product or its injection&#xD;
                  procedure, during or after Fontan surgical palliation.&#xD;
&#xD;
          -  Individuals with severe heart failure that requires heart transplantation&#xD;
&#xD;
          -  Individuals with refractory or worsening arrhythmia&#xD;
&#xD;
          -  Individuals with an automated implantable cardioverter defibrillator (AICD) or&#xD;
             pacemaker&#xD;
&#xD;
          -  Patient with prior surgical complications during the Fontan surgical palliation that&#xD;
             resulted in or could be reasonably expected to significantly decrease cardiac function&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Dearani</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harold M Burkhart</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Oklahoma University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph w Rossano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David M Overman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ram Kumar Subramanyan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Jaggers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Colorado</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benjamin Peeler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ochsner Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Waldemer Carlo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Tweddell, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jason Maynes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital forSick Children</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lynn Padley</last_name>
    <phone>5075771764</phone>
    <email>lynn@regentheranostics.com</email>
  </overall_contact>
  <link>
    <url>http://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>ReGen Theranostics, Inc.</investigator_affiliation>
    <investigator_full_name>Timothy J Nelson, MD, PhD</investigator_full_name>
    <investigator_title>Program Director</investigator_title>
  </responsible_party>
  <keyword>Hypoplastic Left Heart Syndrome</keyword>
  <keyword>HLHS</keyword>
  <keyword>Congenital Heart Disease</keyword>
  <keyword>Umbilical Cord Blood</keyword>
  <keyword>UCB</keyword>
  <keyword>Cord Blood</keyword>
  <keyword>Stem Cells</keyword>
  <keyword>Regenerative therapy</keyword>
  <keyword>Stage III Fontan</keyword>
  <keyword>Fontan surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

